–Company Expects to Announce Phase 2 Clinical Data In First Quarter of 2012– LOS ANGELES – November 17, 2011 – Ritter Pharmaceuticals, Inc. (Ritter) announced today the last patient has completed treatment in its Phase 2 study for RP-G28, a first-in-class treatment for symptoms associated with lactose intolerance. This multicenter, randomized, double-blind, placebo-controlled, parallel group [...]

Leave Your Comments »